Zogenix Receives 2011 Drug Delivery Partnerships Innovation Award for SUMAVEL(R) DosePro(TM)
February 09, 2011 07:30 ET
|
Zogenix
SAN DIEGO, Feb. 9, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. ("Zogenix") (Nasdaq:ZGNX) today announced that it has received the 2011 Drug Delivery Partnerships™ ("DDP") Innovation Award in the...
Zogenix to Participate in the Leerink Swann Hot Topics in Therapeutics Roundtable Conference
February 08, 2011 16:32 ET
|
Zogenix
SAN DIEGO, Feb. 8, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) today announced that Chief Executive Officer Roger L. Hawley, along with Executive Vice President and Chief Financial Officer...
Zogenix and Desitin Announce Marketing Approval for SUMAVEL(R) DosePro(TM) in Germany and the United Kingdom
January 06, 2011 07:30 ET
|
Zogenix
SAN DIEGO and HAMBURG, Germany, Jan. 6, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. ("Zogenix") (Nasdaq:ZGNX) and Desitin Pharmaceuticals GmbH ("Desitin") today announced that the Federal Institute for...
Zogenix Announces Partial Exercise of Over-Allotment Option for Initial Public Offering
December 23, 2010 07:30 ET
|
Zogenix
SAN DIEGO, Dec. 23, 2010 (GLOBE NEWSWIRE) -- Zogenix, Inc. ("Zogenix") (Nasdaq:ZGNX) announced today that the underwriters of its recently completed initial public offering of common stock have...
Zogenix Receives 2010 Most Innovative Product Award for SUMAVEL(R) DosePro(TM)
December 13, 2010 07:30 ET
|
Zogenix
SAN DIEGO, Dec. 13, 2010 (GLOBE NEWSWIRE) -- Zogenix, Inc. ("Zogenix") (Nasdaq:ZGNX) today announced that CONNECT, a regional San Diego nonprofit organization, selected SUMAVEL® DosePro™...
Zogenix and Desitin Announce First European Marketing Approval for SUMAVEL(R) DosePro(TM)
December 02, 2010 07:30 ET
|
Zogenix
SAN DIEGO and HAMBURG, Germany, Dec. 2, 2010 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) and Desitin Pharmaceuticals GmbH today announced that the Danish Medicines Agency of Denmark has approved...
Zogenix Announces Completion of Enrollment in ZX002 Phase 3 12-Month Safety Study
November 30, 2010 07:30 ET
|
Zogenix
SAN DIEGO, Nov. 30, 2010 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) today announced completion of enrollment in its open-label Phase 3 safety study (Study 802) of ZX002. ZX002 is a novel, oral,...
Zogenix Announces Pricing of Initial Public Offering
November 22, 2010 20:45 ET
|
Zogenix
SAN DIEGO, Nov. 22, 2010 (GLOBE NEWSWIRE) -- Zogenix, Inc. ("Zogenix") (Nasdaq:ZGNX) announced today the pricing of its initial public offering of 14,000,000 shares of its common stock at $4.00 per...